Literature DB >> 19109231

The temporal profile of the anti-PF4/heparin immune response.

Andreas Greinacher1, Thomas Kohlmann, Ulrike Strobel, Jo-Ann I Sheppard, Theodore E Warkentin.   

Abstract

The immune response in heparin-induced thrombocytopenia (HIT) is puzzling: heparin-naive patients can develop IgG antibodies and clinical HIT as early as day 5, and evidence for an anamnestic response on heparin reexposure is lacking. We assessed daily serum samples by anti-PF4/heparin enzyme-immunoassay (EIA) in patients receiving heparin thromboprophylaxis. Of 435 patients, 56.1% showed an increase in EIA optical density (OD) of more than or equal to 15%, with more than 90% starting between days 4 and 14. After reaching maximum reactivity by days 10 to 12, ODs declined despite heparin continuation, including in 2 patients with clinical HIT. Individual IgG/A/M classes showed identical time of onset (median, day 6). Most (58.7%) antibody-positive patients developed all 3 Ig classes; only 11.3% lacked IgG response. IgG/A/M increase usually occurred simultaneously (+/- 1 day) with no general tendency for IgM precedence. Consistent with the transient immune response, none of the IgG-EIA-positive (OD > 0.5) patients at discharge developed clinically evident thrombosis during extended low-molecular-weight heparin thromboprophylaxis. The rapid onset of the anti-PF4/heparin immune response, its transience, and the simultaneous appearance of antibodies of different classes with no IgM precedence suggest short-term activation of B cells that have previously undergone Ig-class switching even without previous pharmacologic heparin exposure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19109231     DOI: 10.1182/blood-2008-08-173062

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling.

Authors:  Cunji Gao; Brian Boylan; Juan Fang; David A Wilcox; Debra K Newman; Peter J Newman
Journal:  Blood       Date:  2011-03-02       Impact factor: 22.113

2.  Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery.

Authors:  Seiji Bito; Shigeki Miyata; Kiyoshi Migita; Mashio Nakamura; Kazuhito Shinohara; Tomotaro Sato; Takeharu Tonai; Motoyuki Shimizu; Yasuhiro Shibata; Kazuhiko Kishi; Chikara Kubota; Shinnosuke Nakahara; Toshihito Mori; Kazuo Ikeda; Shusuke Ota; Takeshi Minamizaki; Shigeru Yamada; Naofumi Shiota; Masataka Kamei; Satoru Motokawa
Journal:  Blood       Date:  2015-12-09       Impact factor: 22.113

Review 3.  Immune pathogenesis of heparin-induced thrombocytopenia.

Authors:  Sanjay Khandelwal; Gowthami M Arepally
Journal:  Thromb Haemost       Date:  2016-07-28       Impact factor: 5.249

4.  Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study.

Authors:  Sixten Selleng; Kathleen Selleng; Sigrun Friesecke; Matthias Gründling; Sven-Olaf Kuhn; Ricarda Raschke; Olivia J Heidecke; Carsten Hinz; Gregor Hron; Theodore E Warkentin; Andreas Greinacher
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

5.  Critical role for mouse marginal zone B cells in PF4/heparin antibody production.

Authors:  Yongwei Zheng; Mei Yu; Andrew Podd; Liudi Yuan; Debra K Newman; Renren Wen; Gowthami Arepally; Demin Wang
Journal:  Blood       Date:  2013-03-04       Impact factor: 22.113

6.  Optimization of a murine immunization model for study of PF4/heparin antibodies.

Authors:  S Suvarna; R Qi; G M Arepally
Journal:  J Thromb Haemost       Date:  2009-02-24       Impact factor: 5.824

7.  Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery.

Authors:  T J Gluckman; J B Segal; S P Schulman; E P Shapiro; T S Kickler; M M Prechel; J V Conte; J M Walenga; I Shafique; J J Rade
Journal:  J Thromb Haemost       Date:  2009-06-23       Impact factor: 5.824

8.  Prospective multicentre cohort study of heparin-induced thrombocytopenia in acute ischaemic stroke patients.

Authors:  Hiroyuki Kawano; Haruko Yamamoto; Shigeki Miyata; Manabu Izumi; Teruyuki Hirano; Naomi Toratani; Isami Kakutani; Jo-Ann I Sheppard; Theodore E Warkentin; Akiko Kada; Shoichiro Sato; Sadahisa Okamoto; Kazuyuki Nagatsuka; Hiroaki Naritomi; Kazunori Toyoda; Makoto Uchino; Kazuo Minematsu
Journal:  Br J Haematol       Date:  2011-06-14       Impact factor: 6.998

9.  A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.

Authors:  Jason H Karnes; Robert M Cronin; Jerome Rollin; Alexander Teumer; Claire Pouplard; Christian M Shaffer; Carmelo Blanquicett; Erica A Bowton; James D Cowan; Jonathan D Mosley; Sara L Van Driest; Peter E Weeke; Quinn S Wells; Tamam Bakchoul; Joshua C Denny; Andreas Greinacher; Yves Gruel; Dan M Roden
Journal:  Thromb Haemost       Date:  2014-12-11       Impact factor: 5.249

10.  Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report.

Authors:  Yoshitaka Furuto; Mariko Kawamura; Jumpei Yamashita; Takahiro Yoshikawa; Akio Namikawa; Rei Isshiki; Hiroko Takahashi; Yuko Shibuya
Journal:  BMC Nephrol       Date:  2021-06-14       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.